Isatuximab vs Lumrotatug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
Isatuximab
Marketed by Sanofi
NCT02990338 · Phase 3 · completed
Participants were randomized 1:1 to isatuximab plus pomalidomide and dexamethasone or pomalidomide and dexamethasone alone, but the study was open-label rather than double-blind. The primary clinical endpoint, progression-free survival, was met: median survival was 11.53 versus 6.47 months, with a hazard ratio of 0.596 and p=0.0005.
Next expected readout: November 2026 · NCT06517017 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279) (met)
Result source: NCT02990338
Lumrotatug
Developed by Timberlyne Therapeutics and partners
NCT04818372 · Phase 1 · status unknown
This is an early, single-arm, open-label safety and dose-finding study with no randomization or comparator group, so it cannot show whether CM313 works better than another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: May 2030 · NCT07910903 (registry estimate)
Reported efficacy
Dose escalation: Number of Participants with a Dose-Limiting Toxicity (DLT) (Up to 21 days after the first dose); Dose escalation and Dose expansion: Incidence, severity, and outcome of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 (Up to 30 days after the last dose of CM313 or until the start of subsequent anticancer therapy, if earlier); Dose expansion: To evaluate the activity of CM313 in combination with Rd/Dexamethasone as assessed by overall response rate (ORR) in RRMM patients (Up to 24 months): CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
Result source: NCT04818372
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Isatuximab | Lumrotatug |
|---|---|---|
| PFS, median | 11.5 vs 6.5vs Pomalidomide + DexamethasoneNCT029903387 other results
| —Trial running · NCT07910903 |
| OS, median | 24.6 vs 17.7vs Pomalidomide + DexamethasoneNCT029903381 other result
| —Trial running · NCT07910903 |
| ORR | 60.4% vs 35.3%vs Pomalidomide + DexamethasoneNCT029903387 other results
| —Trial running · NCT07910903 |
| VGPR or better | 31.8% vs 8.5%vs Pomalidomide + DexamethasoneNCT029903381 other result
| —Trial running · NCT07910903 |
| MRD negativity | —Not posted · NCT05804032 | —Trial running · NCT07910903 |
PFS, median
- Isatuximab
- 11.5 vs 6.5vs Pomalidomide + DexamethasoneNCT02990338
7 other results
- 35.6 vs 19.1 NCT03275285
- 41.7 vs 20.8 NCT03275285
- 7.5 vs 3.7 NCT02990338
- 5.6 NCT02812706
- 2.9 NCT03194867
- 3.8 NCT03194867
- 3.0 NCT03194867
- Lumrotatug
- —Trial running · NCT07910903
OS, median
- Isatuximab
- 24.6 vs 17.7vs Pomalidomide + DexamethasoneNCT02990338
1 other result
- 12.8 NCT03194867
- Lumrotatug
- —Trial running · NCT07910903
ORR
- Isatuximab
- 60.4% vs 35.3%vs Pomalidomide + DexamethasoneNCT02990338
7 other results
- 86.6% vs 82.9% NCT03275285
- 32.1% NCT02812706
- 11.8% NCT03194867
- 25% NCT03194867
- 22.2% NCT03194867
- 60% NCT02812706
- 66.7% NCT02812706
- Lumrotatug
- —Trial running · NCT07910903
VGPR or better
- Isatuximab
- 31.8% vs 8.5%vs Pomalidomide + DexamethasoneNCT02990338
1 other result
- 72.6% vs 56.1% NCT03275285
- Lumrotatug
- —Trial running · NCT07910903
MRD negativity
- Isatuximab
- —Not posted · NCT05804032
- Lumrotatug
- —Trial running · NCT07910903
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Isatuximab: 4 of 4 rows · Lumrotatug: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Isatuximab |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3 show 8 more resultsn/a: no completion milestone NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 —Phase 1: Isatuximab+Cemiplimab Q2W NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 2: Isatuximab NCT03194867 · Phase 1/2 · registry result, not featured evidence 2.8%Phase 2: Isatuximab + CemiplimabQ2 NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2:Isatuximab + CemiplimabQ4W NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone20 mg/kg NCT02812706 · Phase 1/2 · registry result, not featured evidence —20 mg/kg NCT02812706 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone10 mg/kg NCT02812706 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | 14.3%a NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3 show 8 more results16.2% NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 —Phase 1: Isatuximab+Cemiplimab Q2W NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2: Isatuximab NCT03194867 · Phase 1/2 · registry result, not featured evidence —Phase 2: Isatuximab + CemiplimabQ2 NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2:Isatuximab + CemiplimabQ4W NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination 40%20 mg/kg NCT02812706 · Phase 1/2 · registry result, not featured evidence —20 mg/kg NCT02812706 · Phase 1/2 · registry result, not featured evidence 0%10 mg/kg NCT02812706 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 73.7%a NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3 show 8 more results72.9% NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 33.3%Phase 1: Isatuximab+Cemiplimab Q2W NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination 51.5%Phase 2: Isatuximab NCT03194867 · Phase 1/2 · registry result, not featured evidence 45.9%Phase 2: Isatuximab + CemiplimabQ2 NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination 60%Phase 2:Isatuximab + CemiplimabQ4W NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination 40%20 mg/kg NCT02812706 · Phase 1/2 · registry result, not featured evidence 39.3%20 mg/kg NCT02812706 · Phase 1/2 · registry result, not featured evidence 33.3%10 mg/kg NCT02812706 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | a neutropenia 50.7% upper respiratory tract infection 34.9% infusion related reaction 34.2% NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3 show 8 more resultsinfusion related reaction 45.2% upper respiratory tract infection 41.2% diarrhoea 40.7% NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 infusion related reaction 66.7% back pain 33.3% chills 33.3% NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination infusion related reaction 54.5% diarrhoea 18.2% arthralgia 15.2% NCT03194867 · Phase 1/2 · registry result, not featured evidence infusion related reaction 40.5% fatigue 21.6% back pain 18.9% NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination infusion related reaction 42.9% diarrhoea 20% upper respiratory tract infection 20% NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination 20 mg/kg vomiting 40% anaemia 20% fatigue 20% NCT02812706 · Phase 1/2 · registry result, not featured evidence 20 mg/kg infusion related reaction 42.9% nasopharyngitis 21.4% pyrexia 21.4% NCT02812706 · Phase 1/2 · registry result, not featured evidence 10 mg/kg infusion related reaction 66.7% nasopharyngitis 66.7% back pain 33.3% NCT02812706 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 7 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Isatuximab
show 5 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 8 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Isatuximab's landscape · Lumrotatug's landscape